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Summary 
Interleukin 6 (IL-6) is a major growth factor for tumor plasma cells involved in human multiple 
myeloma (MM). In particular, human myeloma cell lines (HMCL), whose growth is completely 
dependent on addition of exogenous IL-6, can be obtained reproducibly from every patient with 
terminal disease. Four cytokines, ciliary neurotropic factor (CNTF), IL-11, leukemia inhibitory 
factor (LIF), and oncostatin M (OM), use the same transducer chain (signal transducer gpD0) 
as IL-6 and share numerous biological activities with this IL. We found that these four cytokines 
stimulated proliferation and supported the long-term growth of two out of four IL-6-dependent 
HMCL obtained  in our laboratory.  Half-maximal  proliferation  was obtained with cytokine 
concentrations ranging from 0.4 to 1.2 ng/ml for IL-11, LIF, and OM. CNTF worked at high 
concentrations only (90 ng/ml), but addition of soluble CNTF receptor increased sensitivity 
to CNTF 30-fold. The growth-promoting effect of these four cytokines was abrogated by anti- 
gp130 antibodies, contrary to results for anti-IL-6 receptor or anti-IL-6 antibodies. No detectable 
changes in the morphology and phenotype were found when myeloma cells were cultured with 
one of these four cytokines instead of IL-6. Concordant with their IL-6-dependent growth, 
the four HMCL expressed membrane IL-6R and gpD0 detected by FACS  |  analysis. LIF-binding 
chain gene (LIFR) was expressed only in the two HMCL responsive to LIF and OM. 
M 
ultiple myeloma (MM) is a B cell neoplasia affecting 
the late stages of B cell differentiation  (plasma cells). 
We and others have shown that IL-6 is a major growth factor 
for tumor plasma cells in vitro and that treatments with anti- 
IL-6 antibodies could result in blockage of tumor prolifera- 
tion in vivo (1-3). In addition, we have been able to obtain 
human myeloma cell lines  (HMCL)  reproducibly,  whose 
growth is completely dependent on addition of exogenous 
IL-6 (4 and Zhang, X.-G., unpublished results). 
As IL-11, leukemia inhibitory factor (LIF), and oncostatin 
M (OM) share similar biological effects with IL-6 as inducers 
of acute-phase proteins,  stimulators  of thrombopoiesis,  and 
as competence factor for hematopoietic cells (5-8), we inves- 
tigated whether they could support  the growth of human 
myeloma cells. The overlapping biological activities of these 
cytokines is to be explained by their use of multicomponent 
receptors, including a common transducer gp130 unit (9-13). 
gp130 was first identified as an IL-6 signal transducer  (14). 
IL-6 binds to its specific  receptor (IL-6R), with a low affinity 
of about  10-9 M  (15). IL-6R has no transducing activity, 
but the complex formed by IL-6 and IL-6R binds to gp130 
(14), resulting in the formation of a high aff~ty IL-6 receptor, 
dimerization, phosphorylation, and activation of the trans- 
ducer gp130 (14, 16). LIF was initially shown to bind with 
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(17). The transducer gpl30 was subsequently found to con- 
vert LIFI~ into a high affinity binding site for OM as well 
as LIF (9). Finally, the IL-11 receptor is presently unidentified 
but was recently shown to include the transducer gp130 (12). 
Another cytokine, ciliary neurotropic factor (CNTF),  also 
uses the transducer gp130. It has a more restricted spectrum 
of biological activity than  IL-6, LIF, or OM, possibly be- 
cause of restricted expression of the CNTF binding protein 
(termed CNTFKot) found mainly in neuronal tissues (18). 
CNTFKc~ binds CNTF with low affinity (18). This receptor 
has no cytoplasmic tail and is linked to the cell membrane 
through glycosyl phosphatidylinositol. Addition of CNTFKot 
to the LIFKB/gp130 complex has been shown to convert a 
functional  LIF  or  OM  receptor  into  a  functional  CNTF 
receptor (19).  CNTFKot and IL-6K share strong homolo- 
gies (15, 18), and a unique feature is that their soluble forms 
have an agonist activity, whereas all known soluble cytokine 
receptors have an antagonist activity. When bound to their 
respective ligands, they can activate the transducer complex 
(14,  20,  21). 
As noted above, the common use of the IL-6 signal trans- 
ducer gp130 by CNTF,  IL-11,  LIF,  and OM may account 
for their  overlapping biological effects with  IL-6.  An im- 
mediate consequence could be that these four cytokines, like 
IL-6, are also involved in numerous diseases: infectious, au- 
toimmune,  and  cancer  diseases,  and  particularly  human 
MM (6). 
We report here that cytokines CNTF, IL-11, LIF, and OM 
are potent growth factors for human myeloma ceils.  Their 
myeloma cell growth factor activity is inhibited by anti-g'pl30 
antibodies unlike  anti-IL-6  or anti-IL-6R  antibodies. 
Materials  and Methods 
HMCL.  The four HMCL (XG-1, XG-2, XG-4, XG-6) were 
obtained by culturing freshly explanted mydoma cells from patients 
with terminal disease with a combination  of II.-6 and GM-CSF 
(4 and Zhang, X.-G., unpublished results). These HMCL have a 
plasma cell phenotype  and the same immunoglobulin  gene rear- 
rangements as patients' tumor cells, and their growth is completely 
dependent on addition of IL-6. Their characteristics are reported 
elsewhere (4 and Zhang, X.-G., manuscript in preparation). HMCL 
were free of mycoplasma contamination  and were routinely cul- 
tured in RPMI 1640 supplemented with 5% FCS and 1 ng/ml 
of recombinant  (r)ID6. 
HMCL Proliferation  Assay.  To investigate their responsiveness 
to various cytokines, XG ceils were washed once with culture 
medium, incubated for 5 h at 370C in culture medium alone, and 
washed again twice. Cells were then cultured at various concentra- 
tions in 96-well fiat-bottomed microplates for 2 or 5 d with either 
culture medium alone or graded concentrations of various cytokines. 
BE-8 anti-Ib6, BIL-6 anti-II~6P,, and GPX7 and GPZ35 anti-gp 
130 mAbs (22) were added at the beginning  of the cultures (final 
concentration  10/xg/ml).  A mouse purified IgG1 (Bb5) was used 
as control  antibody. 0.5/~Ci of tritiated  thymidine  (25 Ci/mM; 
CEA, Saclay, France) was added for the last 8 h of culture,  and 
tritiated thymidine incorporation was determined as reported else- 
where (23). 
Phenotyl~ Analysis.  The phenotype of the XG lines was studied 
using mAbs to various human antigens and an anti-mouse Ig anti- 
body coupled with fluorescein isothiocyanate (Immunotech,  Mar- 
seilles, France). Fluorescence analysis was performed with a flow 
cytometer (ATC 3000/KCA 3000; Bruker, Wissembourg, France). 
Antibodies to CD19, CD21, CD23, CD28, CD32, CD38, CD40, 
and CD56 antigens were purchased from Immunotech.  The char- 
acteristics of MT18 anti-IL-6K and GPX7 and GPZ35 anti-gpl30 
were previously reported (22, 24). Cytoplasmic immunoglobulin 
heavy and light chains were detected by specific  antibodies coupled 
with fluorescein (Kallestadt, Austin,  TX). 
Detection of LIFRfl Expression by PCR.  Aliquots of XG cells 
(50  x  10  ~ cells), cultured with 1 ng/nd of rIL-6, were harvested 
during  the exponential growth phase and frozen in nitrogen  for 
RNA studies, cDNA was synthesized from 1/~g total KNA from 
each cell line. 35 cycles of PCR (45 s at 94~  45 s at 650C, 90 s 
at 72~  followed by 3-min extension at 720C were carried out 
using primers corresponding to nucleotides 155-175 and 1501-1525 
of LIFt~ sequence (17). This gives a 1.37-kb product.  15 ~1 of 
each 25-/~1 PCR reaction were electrophoresed on 1.5% agarose 
gel in TAE buffer and transferred onto Hybond filters (Amersham, 
Les Ulis, France). Filters were hybridized with a LIFR~ cDNA 
probe  labeled with  [32P]dCTP by a random  priming  method 
(Boehringer  Mannheim,  Meylan,  France) and were exposed to 
Kodak XAR5 films at  -70~  for 2 h. 
Immunoglobulin Production.  Immunoglobulin  production  was 
measured in culture supernatants of XG cells using an ELISA and 
anti-human heavy and light immunoglobulin chains purchased from 
Immunotech.  Supernatants were prepared by culturing  5  x  105 
cells/ml for 2 d with the various cytokines. 
Reagents.  Purified rlL-6 was provided by D. Stinchcomb (Syn- 
ergen, Boulder, CO), tOM by M. Shoyab (Bristol Myers Squibb, 
Seattle, WA),  rCNTF and and rCNTFRc~  by Dr.  G. D.  Yan- 
copoulos (tLegeneron, Tarrytown, NY), rLIF by A. Godard (IN- 
SEtLM U211, Nantes, France), and neutralizing BR-6 anti-Ib6R 
and B-E8 anti-IL-6 mAb by Dr. J. Wijdenes (Innotherapie, Besan~on, 
France). 
Results 
CNTF, IL-I1, LIF, and OM Are Growth Factors  for Human 
Myeloma Cells.  Results are shown in Figs.  1 and 2. XG-1, 
XG-2,  XG-4,  and XG-6 HMCL could not proliferate and 
grow without addition of an exogenous cytokine, and high 
proliferation  was  induced  by  rlL-6.  The  four  cytokines 
(rCNTF,  rlL-11,  rLIF,  and tOM)  also induced significant 
proliferation  of XG-4 and XG-6 myeloma cells. 
Proliferation  of XG-1  and XG-2 ceils was supported by 
rlL-6 alone. Half-maximal proliferation of XG-4 and XG-6 
myeloma ceils was induced by 100 and 70 pg/ml of rlL-6, 
800, and 1200 pg/ml of rlL-11, 324 and 470 pg/mt of rLIF, 
and 440 and 410 pg/ml  of tOM,  respectively. Only XG-4 
cells were significantly stimulated by large concentrations of 
rCNTF (half-maximal proliferation induced by 90 ng/ml of 
rCNTF).  XG-6 cells were only marginally stimulated,  and 
XG-1 and XG-2 cells were not stimulated by rCNTF (Fig. 1). 
rlL-11, rLIF, or rOM supported the long-term growth of 
XG-4 and XG-6 (>6 too), unlike XG-1 and XG-2 HMCL 
(Fig.  2), making it possible to obtain XG-4 or XG-6 sub- 
clones whose growth was strictly dependent on addition of 
the initial cytokine. XG-4, but not XG-6 HMCL, could be 
grown with  rCNTF  alone (Fig.  2). 
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Figure  1.  Proliferative  response of human mydoma 
cell lines to I]--6, CNTF, ILll, LIF, and OM. XG- 
cells were cultured at a concentration of 105 cells/ml 
for 5 d with graded dilutions of a cytokine prepara- 
tion containing either  1 ng/ml of rlb6, 810 ng/ml 
of rCNTF, 100 ng/ml of rIbtl, 10 rig/m1 of rLIF, 
or 10 ng/ml of rOM. Proliferation was assayed using 
tritiated thymidine incorporation, and results are mean 
values determined  on se~tuplate culture wells. 
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No changes in the morphology, phenotype or immuno- 
globulin secretion of XG-4 and XG-6 myeloma cells were 
found when cultured for more than 4 wk with IL-11, LIF, 
or OM instead of IL-6 (results not shown). 
Myeloma-Cell Growth Factor  Activity of CNTF, IL-II, LIF,, 
and OM Was Mediated Through IL-6 Signaling gpl30 Trans- 
duc~  Proliferation of XG-4 and XG-6 cells induced by rIL,6, 
rCNTF, rib11, rLIF, or rOM was completdy inhibited by 
anti-gp130 mAb (Fig. 3). Anti-lL-6R or anti-IL-6 mAb com- 
pletely inhibited rlL-6-induced proliferation and did not affect 
growth induced by rCNTF, rIL-11, rLIF, or rOM (Fig. 3). 
Soluble CNTFRc~ Potentiated  the CNTF Res~nse of  HMCL. 
As noted above, rCNTF induced a proliferative response in 
XG-4 cells at high concentration only (half-maximal prolifer- 
ation obtained with 90 ng/ml). Addition of soluble CNTFKc~ 
increased the sensitivity of XG-4 cells 30-fold, half-maximal 
proliferation being obtained with 3 ng/ml of rCNTF (Fig. 
4). Again, the potentiating effect of sCNTFKc~ was com- 
pletely abrogated by anti-gp130  mAb (Fig. 4). 
Expression of  LIFP,  q8 Gene by XG Cells.  The four HMCL 
expressed membrane IL-6K and the transducer gp130, which 
could be detected by a specific mAb and FACS  |  analysis 
(Becton Dickinson & Co., Mountain View, CA).  LIFRB 
Figure 2.  Long-term growth of human myeloma cell lines stimulated 
by Ib6, CNTF, Ib11, LIE or OM. XG-4 or XG-6 cells were cultured 
at a cell concentration of 10  s cells/ml with either no exogenous cytokine, 
or 1 ng/ml of rlL-6, 300 ng/ml of rCNTF, 10 ng/ml of rlI~11, 10 ng/ml 
of rLIF, or 10 ng/ml of tOM. For each culture group, XG cells  were diluted 
every 4 d at a cell concentration of 10  s cells/ml in fresh culture medium 
containing the initial cytokine concentration.  Results are the cumulative 
numbers of cells generated in each culture group. 
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Figure  3.  Growth factor activity of CNTF, IL-11, LIF, and OM is 
abrogated by anti-gp130 antibodies. XG-4 and XG-6 cells were cultured 
at a concentration of 105 cells/ml for 5 d with either no cytokine, 300 
pg/ml of rIL-6, 300 ng/ml of rCNTF,  10 ng/ml of rlL-11, 10 ng/ml of 
rLIF, or 10 ng/ml of tOM. For each cytokine, culture groups containing 
either a control antibody, 10 rig/m1 of  GPX7 and GtrZ35 anti-gp130  mAb, 
10 #g/mi of BK-6 anti-lb6K mAb, or 10 #g/ml of B-E8 anti-IL-6  mAb 
were prepared. Proliferation was assayed  by tritiated thymidine incorpora- 
tion.  Results are mean values determined on sextuplate culture wells. 
mRNA was detected by PCR amplification  in XG-4 and XG-6 
ceils but not in XG-1  and XG-2 cells (Fig. 5). 
Discu.ion 
We and  others have shown  that  IL-6 is a  major growth 
factor for the proliferation of tumor plasma cells in human 
Figure  5.  Detection of LIFR,  fl gene expression in XG cells by PCR. 
cDNA was synthesized from 1/zg total R_NA from each XG cell line. 
35 cycles of PCIL (45 s at 94~  45 s at 60"C, and 90 s at 72"C) were 
carried out  using  primers  corresponding  to  nudeotides  155-175 and 
1501-1525 of LIFILfl  sequence. The 1.37-kb product of PCR was electro- 
phoresed in 1.5% agarose, transferred onto falters, and hybridized with 
a LIFR43 cDNA probe labeled with 321). 
multiple myeloma (1, 2). In particular, for every patient with 
terminal disease,  IL-6 enables human myeloma cell lines  to 
be obtained whose proliferation is completely dependent on 
addition  of exogenous  IL-6 (4  and  Zhang,  X.-G.,  unpub- 
lished  results). 
In this work,  we showed that IL-11, OM,  and LIF were 
growth  factors similar to IL-6 for two of the four HMCL 
studied. These cytokines allowed us to obtain subclones whose 
growth is completely dependent  on addition of IL-11, LIF, 
or OM.  The four HMCL  expressed membrane IL-6R and 
the transducer  l~p130 which could be detected by a  specific 
mAb and FACS  |  analysis. The sensitivity to LIF or OM was 
found to correlate with the presence ofLIFRfl mRNA which 
was detected in XG-4 and XG-6 but not in XG-1 and XG-2 
cells. It is likely that these two HMCL also express an IL-11- 
binding  protein  not  presently  identified. 
XG-4 and XG-6 cells were stimulated  only at high con- 
centrations of CNTF (half-maximal proliferation induced by 
90 ng/ml).  This biological effect can be explained by a pos- 
sible low affinity interaction of CNTF with the heterodimer 
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Figure  4.  Potentialization of CNTF response by soluble 
CNTF receptor. 10  s XG-4 cells/ml were cultured for 5 d 
with various CNTF concentrations and various concentra- 
tions of sCNTFRot (0-50 nM). In one culture group, 10/~g/ml 
of the GPX7 and GtrZ35  anti-gpD0 mAb were added. Prolifer- 
ation was assayed using tritiated  thymidine incorporation. 
Results are mean values  determined  on sextuphte culture wells. LIFRB and gp130 in the absence of CNTFRot, as previously 
reported (20).  This was confirmed by the 30-fold increase 
in the sensitivity of myeloma cells to CNTF in the presence 
of soluble CNTFRcx. Soluble IL-6R can also potentiate the 
response of cells to IL-6 (14, 21). Thus, soluble forms of these 
receptors bound to their ligand actually behave like cytokines 
that are able to activate their transducer complex. This con- 
cept is supported by the fact that IL-12 is a heterodimer com- 
posed of one chain homologous to IL-6 and another chain 
homologous to IL-6R (25).  Our previous finding that  the 
presence of high concentration of soluble IL-6R in patients 
with MM is associated with poor prognosis might in part 
be explained by this concept (26). Soluble forms of LIFRB 
and gp130 have also been found in the serum of mice or hu- 
mans. These soluble forms have an antagonist activity (27, 28). 
Thus, we showed that mechanisms previously  demonstrated 
with transfected cells are operational in freshly obtained tumor 
cell lines  (9-21).  In a recent  study,  Nishimoto  et al.  (29) 
demonstrated that LIF and OM are also growth factors for 
freshly explanted myeloma cells. In the case of multiple my- 
doma,  we previously showed that  IL-6 overproduction in 
vivo was associated with poor prognosis (30) and that treat- 
ment  with  anti-IL-6  antibodies  could result  in  complete 
blockage of tumor proliferation in vivo (3). It is now essen- 
tial to determine whether CNTF, IL-11,  LIF, OM, sotuble 
IL-6R, or soluble CNTFRo~ is produced in tumor prolifera- 
tion sites in patients with MM. In particular, it is important 
to find out whether resistance to therapy in patients treated 
with  anti-IL-6 antibodies is associated with production  of 
one of these cytokines in vivo (3). 
The fact that the 5 cytokines using the same gp130 trans- 
ducer are myeloma cell growth factors suggests that the con- 
cept of multiple myeloma as an IL-6-related disease should 
be extended to that of a gp130-dependent disease. Kaposi sar- 
coma, another IL-6-related disease, is also related to OM (31). 
Thus, agents able to block the activation of gp130 without 
killing cells expressing it (i.e., almost every cell in the body) 
should be extremely useful for treatment  of the numerous 
diseases  initially considered to be IL-6 related. 
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